After a week of intense haggling, the World Health Assembly has adopted a controversial resolution designed to improve access to medicines. Yet the effort received decidedly mixed reviews over language that bolstered transparency into drug pricing, but maintained a curtain around key R&D costs.

The resolution, which was introduced last February by Italy and co-sponsored by 20 other countries, is seen as a vehicle by cash-strapped governments to control their drug spending, an issue that has reverberated around the world and, increasingly, engulfed wealthy nations, as well.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy